A Patient with Sickle Cell Disease and Recurrent Venous Thromboembolism after Renal Transplantation
Thalassemia Reports · 2022
DOI: 10.3390/thalassrep12030013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thalassemia Reports, 2022. Verfasst von Rosario Di Maggio und 7 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
Venous thromboembolism (VTE) is a life-threatening complication, especially in case of recurrence. The appropriate duration of anticoagulant treatment following the first event is crucial. Risk factors that increase the risk of recurrence of VTE are many, and include medications, kidney disease, renal transplantation (RT), and a diagnosis of sickle cell disease (SCD). There are currently no guidelines that define the duration of anticoagulant therapy after the first event in a patient with RT. We report a case of recurring episodes of VTE after RT in a SCD patient. Our case suggests that the use of a long-term anticoagulant treatment may be recommended in patients with SCD and RT after the first event of VTE.
Zitieren
APA
Maggio, R. D., Giuliano, A., Renda, D., Calvaruso, G., Raso, S., Pitrolo, L., Carroccio, A., & Maggio, A. (2022). A Patient with Sickle Cell Disease and Recurrent Venous Thromboembolism after Renal Transplantation. Thalassemia Reports. https://doi.org/10.3390/thalassrep12030013
Vancouver
Maggio RD, Giuliano A, Renda D, Calvaruso G, Raso S, Pitrolo L, et al. A Patient with Sickle Cell Disease and Recurrent Venous Thromboembolism after Renal Transplantation. Thalassemia Reports. 2022. doi:10.3390/thalassrep12030013
BibTeX
@article{Maggio2022,
author = {Maggio, Rosario Di and Giuliano, Alessandra and Renda, Disma and Calvaruso, Giuseppina and Raso, Simona and Pitrolo, Lorella and Carroccio, Antonio and Maggio, Aurelio},
title = {A Patient with Sickle Cell Disease and Recurrent Venous Thromboembolism after Renal Transplantation},
journal = {Thalassemia Reports},
year = {2022},
doi = {10.3390/thalassrep12030013}
}
EUVIMED